AstraZeneca: Carcinoma, Hepatocellular trials
The registry lists 25 Carcinoma, Hepatocellular studies with AstraZeneca as lead sponsor. 7 are open to participants now and 4 have results posted.
Phase 1 7Phase 2 6Phase 3 6No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CHARM Hepatocellular Carcinoma MEA StudyRecruitingNCT07650773
- MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.RecruitingNCT07607769
- A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingNCT06921785Phase 3
- First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid TumoursRecruitingNCT06795022Phase 1/2
- Imjudo & Imfinzi PMSRecruitingNCT06544629
- LTFU for All Cell and Gene Therapy StudiesNot yet recruitingNCT06194461
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT03298451Phase 3Results posted
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results posted
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular CarcinomaCompletedNCT01839604Phase 1Results posted
- MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.CompletedNCT01498952Phase 1Results posted
- Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2
- Brazilian Reality of Hepatocellular CarcinomaCompletedNCT06230328
- A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaActive, not recruitingNCT06084884Phase 1/2
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
- Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompletedNCT05667064
- Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3
- Himalaya Early Access ProgramApproved for marketingNCT05345678
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
- OREIOS International StudyCompletedNCT05239507
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
- A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
- A Study of MEDI-575 in Patients With Advanced Solid MalignanciesCompletedNCT01102400Phase 1
- Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer PatientsCompletedNCT00999882Phase 1